FR3064177A1 - COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF PRURIGINOUS INFLAMMATORY DERMATOSES - Google Patents

Abstract

The invention relates to a cosmetic and / or dermatological composition intended for the treatment of pruriginous inflammatory dermatoses caused by cutaneous neurogenic inflammations comprising as active principle the Uriage thermal water associated with the ingredients that are acceptable in the cosmetic field, said composition having a soothing effect on the said dermatoses and to prevent and reduce excess stimulation and superficial accumulation of cutaneous cells, the thermal water representing between 5 and 20% by mass of thermal water Uriage. Application to the preparation of creams and fluids around the eyes.

Description

© Publication no .: 3,064,177 (to be used only for reproduction orders)

©) National registration number: 17 70291 ® FRENCH REPUBLIC

NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY

COURBEVOIE © Int Cl ⁸ : A 61 K8 / 19 (2017.01), A 61 Q 19/00

A1 PATENT APPLICATION

©) Date of filing: 23.03.17. © Applicant (s): LABORATOIRES DERMATOLO- (© Priority: URIAGE GICS— FR. @ Inventor (s): LEFEUVRE LUC. ©) Date of public availability of the request: 28.09.18 Bulletin 18/39. ©) List of documents cited in the report preliminary research: Refer to end of present booklet (© References to other national documents ® Holder (s): DERMATOLOGICAL LABORATORIES related: OF URIAGE. ©) Extension request (s): (© Agent (s): CABINET CELANIE Company by simplified actions.

FR 3 064 177 - A1

COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF PRURIGINOUS INFLAMMATORY DERMATOSIS.

_ The invention relates to a cosmetic and / or dermatological composition intended for the treatment of pruritic inflammatory dermatoses caused by skin neurogenic inflammations comprising as active ingredient Uriage thermal water associated with the admissible ingredients in the cosmetic field, said composition having a soothing effect on said dermatoses and making it possible to prevent and reduce excess stimulation and the superficial accumulation of skin cells, the thermal water representing between 5 and 20% by mass of Uriage thermal water.

Application to the preparation of creams and fluids around the eyes.

The technical sector of the present invention is that of cosmetic and / or dermatological compositions intended for treating dermatoses caused by neurogenic skin inflammations.

Skin inflammations have been studied and treated for a very long time. These inflammations result in redness, itching, erythema, dander, lesions. First of all, the treatment consists in maintaining good hydration of the skin, since dryness is a factor of crisis. Creams and lotions are generally used. To treat these inflammations, anti-inflammatory drugs (corticosteroids), antihistamines and phototherapy (puvatherapy) are prescribed, for example.

These effective treatments have significant drawbacks which greatly limit their long-term use and lead to their restriction to the most severe or acute cases. Corticosteroids can cause a thinning of the antihistamines affecting the skin, the immune system with risks of time, and puvatherapy increases skin cancers.

In addition, all of these treatments increase the risk of worsening inflammatory pruritic dermatoses.

The object of the present invention is therefore to provide a cosmetic and / or dermatological composition having a soothing effect on pruritic inflammatory dermatosis caused by neurogenic skin inflammation, which does not have the drawbacks of known treatments.

The subject of the invention is therefore a cosmetic and / or dermatological composition intended for the treatment of pruritic inflammatory dermatoses caused by cutaneous neurogenic inflammations comprising as active principle Uriage thermal water associated with the admissible ingredients in the cosmetic field, said composition having a soothing effect on said dermatoses and making it possible to prevent and reduce excess stimulation and the superficial accumulation of skin cells.

According to a characteristic of the invention, the composition comprises between 5 and 20% by mass of Uriage thermal water.

According to another characteristic of the invention, Uriage thermal water comprises:

- between 40 mg / L and 600 mg / L of calcium, and / or salts and / or derivatives thereof,

- between 12.5 mg / L and 125 mg / L of magnesium, and / or salts and / or derivatives thereof,

- between 0.455 mg / L and 45.5 mg / L of potassium, and / or of salts and / or derivatives thereof,

- between 23.6 mg / L and 2360 mg / L of sodium, and / or of salts and / or derivatives thereof.

According to yet another characteristic of the invention, the composition is in the form of an eye contour fluid comprising:

- 6% Uriage thermal water,

- 5% dimethicone, 3% glycerin,

- 3% of hydrogenated polyisobutene,

- 2.5% butylene glycol,

- 2.5% shea butter,

- 1.5% of cetearyl ethylhexanoate,

- 1.5% sodium polyacrylate,

- 0.75% acrylates / Cl0-30 alkyl acrylate crosspolymer,

- 0.40% chlorphenesin,

- 0.15% o-cymen-5-ol,

- 0.09% of gum-1 biosaccharide, and

- QSP 100 water.

According to yet another characteristic of the invention, the composition is in the form of an eye contour fluid comprising:

- 9% Uriage thermal water,

- 3% dimethicone,

- 4% glycerin,

- 2% of hydrogenated polyisobutene,

- 2.5% butylene glycol,

- 2.5% shea butter,

- 1.5% of cetearyl ethylhexanoate,

- 1.5% sodium polyacrylate,

- 0.75% acrylates / Cl0-30 alkyl acrylate crosspolymer,

- 0.40% chlorphenesin,

- 0.15% o-cymen-5-ol,

- 0.09% biosaccharide gum-1 and

- QSP 100 water.

According to yet another characteristic of the invention, the composition is in the form of a light cream comprising:

- 15% Uriage thermal water,

- 7% propylheptyl caprylate,

- 4% shea butter,

- 4.5% of cetearyl isononanoate,

- 1.5% cetyl alcohol,

- 1.5% hydrogenated polydecene,

- 1.5% squalane,

- 2.5% butylene glycol,

- 7% glycerin,

- 2% steareth-21,

- 1.2% pentaerythrityl distearate,

- 1.5% sodium polyacrylate,

- 0.75% steareth-2,

- 0.40% chlorphenesin,

- 0.20% citric acid,

- 0.15% of o-cymen-5-ol and 0.30% of xanthan gum, and

- QSP 100 water.

According to yet another characteristic of the invention, the composition is in the form of a light cream comprising:

- 12% Uriage thermal water,

- 5% propylheptyl caprylate,

- 2.5% shea butter,

- 3% of cetearyl isononanoate,

- 2.5% cetyl alcohol,

- 1.5% hydrogenated polydecene,

- 1.5% squalane,

- 2.5% butylene glycol,

- 7% glycerin,

- 2% steareth-21,

- 1.2% pentaerythrityl distearate,

- 1.5% sodium polyacrylate,

- 0.75% steareth-2, 0.40% chlorphenesin,

- 0.20% citric acid, 0.15% o-cymen-5-ol,

- 0.30% xanthan gum, and

- QSP 100 water.

According to yet another characteristic of the invention, the composition is in the form of a rich cream comprising:

- 18% Uriage thermal water,

- 8% propylheptyl caprylate,

- 5% shea butter,

- 4% of cetearyl isononanoate,

- 2% cetyl alcohol,

- 2% hydrogenated polydecene,

- 2% squalane,

- 2.5% butylene glycol,

- 1.5% dimethicone,

- 5% glycerin,

- 2% steareth-21,

- 1.2% pentaerythrityl distearate,

- 1.5% sodium polyacrylate,

- 0.75% steareth-2,

- 0.40% chlorphenesin,

- 0.20% citric acid,

- 0.15% o-cymen-5-ol,

- 0.30% xanthan gum, and

- QSP 100 water.

According to yet another characteristic of the invention, the composition is in the form of a rich cream comprising:

- 20% Uriage thermal water,

- 6% propylheptyl caprylate,

- 6% shea butter,

- 4% of cetearyl isononanoate,

- 2% cetyl alcohol,

- 2% hydrogenated polydecene,

- 2% squalane,

- 2.5% butylene glycol,

- 1.5% dimethicone,

- 5% glycerin,

- 2% steareth-21,

- 1.2% pentaerythrityl distearate,

- 1.5% sodium polyacrylate,

- 0.75% steareth-2,

- 0.40% chlorphenesin,

- 0.20% citric acid,

- 0.15% o-cymen-5-ol,

- 0.30% xanthan gum, and

- QSP 100 water.

A first advantage of the invention lies in the surprising effect of Uriage thermal water for dermatoses. composition

This unique effect of soothing the surprising seems to be linked to this mineral salt water, giving it an isotonic character close to the natural environment of skin cells.

Another advantage of the composition according to the invention is to make available to the nursing staff a treatment for pruritic inflammatory dermatosis which is not aggressive for the skin, which limits the negative reactions of the skin.

Yet another advantage of the composition according to the invention lies in the absence of negative side effects during the treatment of dermatosis.

Yet another advantage of the composition according to the invention is to provide a treatment which directly affects the metabolic pathways of cutaneous neurogenic inflammation and does not attack only the symptoms.

Other characteristics, details and advantages of the invention will appear more clearly on reading the additional description given below.

Neurogenic skin inflammation is an inflammation of the skin caused by the activation of intra-epidermal nerve fibers which causes skin manifestations (redness, pruritus, dander, etc.) grouped under the term of pruritic inflammatory dermatoses, which includes psoriasis, atopic dermatitis or Netherton syndrome.

A peculiarity of neurogenic skin inflammation is to trigger pruritus which can be non-histaminergic.

However, in this pruritus is involved the receptor activated by type 2 proteases (PAR-2), which also plays a role in the metabolic pathway of said inflammation.

There is currently no effective treatment for non-histaminergic pruritus.

Pruritus is not the only symptom caused by neurogenic skin inflammations, but a consequence among a wide and complex spectrum. These inflammations are complex phenomena that have not yet been fully clarified.

The inventor, however, advanced knowledge in this area.

The role of PAR-2 in the secretion of neuropeptides from sensory neurons is well known, and its inflammatory effect on keratinocytes has been demonstrated. Indeed, it is well known that its activation leads to an increase in the secretion of mediators of inflammation in neuronal cells and keratinocytes, as well as a decrease in the secretion of growth factors. These two phenomena lead to a decrease in innervation in sensory neurons, a decrease in the skin barrier, dilation of blood vessels as well as recruitment

It is these processes of immunity, biochemical cells that cause feelings of pain, pruritus and burning, as well as dysfunctions such as red patches, dander, crevices, etc. in affected people.

Uriage thermal water has been known since ancient times for its beneficial effects on the skin. Since then, it has been used to relieve skin conditions. The exact mechanisms of Uriage thermal water action are still poorly understood and are the subject of extensive research by the applicant's laboratories.

This is why the inventor became interested in Uriage thermal water on the expression of the modulated by the activation of PAR-2.

To refine its determination, the inventor proceeded to analyze the effect of the activation of the PAR-2 receptor on cell cultures (differentiated human keratinocytes), by screening the expression of the mediators of inflammation: Connexins 26 and 43, CXCL1 and 2, TNF-alpha, IL-lbeta, TSLP and MMP9.

Connexins 26 and 43 are communicating junction proteins between cells.

CXCL 1 and 2 are cytokines involved in the activation, differentiation and migration of immune cells.

TNF-alpha and IL-lbeta are inflammatory and sensitizing molecules of sensory neurons which stimulate the secretion of other inflammatory cytokines and neuropeptides thus triggering neurogenic cutaneous inflammation and pruritus.

TSLP is a cytokine, the secretion of which triggers atopic dermatosis associated with pruritus in mice by stimulating sensory neurons.

MMP9 is involved in matrix remodeling the effect of extracellular proteins during wound healing, intercellular signaling, inflammation and angiogenesis.

The cells were treated with a PAR-2 agonist and whether or not subjected to a Uriage thermal water bath.

When the cell cultures are treated with a PAR-2 agonist, the expression of the various proteins retained (CX26 and 43, CXCL1 and 2, TSLP, TNF-alpha, IL-lbeta and MMP9) is modified. It is greatly reduced for CX 43 and greatly increased for the others.

We can therefore conclude that the activation of PAR-2 leads to the deregulation of the synthesis of many proteins involved in the mechanisms of inflammation.

When the cells are also treated, in addition to the PAR-2 agonist, with Uriage thermal water, the level of protein expression is substantially identical to the control.

It is therefore seen that Uriage thermal water has a normalizing effect on the metabolic pathways affected by the activation of PAR-2, and therefore a soothing effect on the symptoms resulting therefrom.

Those skilled in the art can therefore envisage its use as an alternative to the conventional treatments well known for dermatoses and associated pruritus.

By way of example, the method of manufacturing rich cream is as follows.

Those skilled in the art use two heating vessels equipped with powerful agitation systems of the foam concentrate type, in order to mix the different ingredients.

In the first container, the water-soluble and water-dispersible ingredients are mixed: water, Uriage thermal water, butylene glycol, glycerin, sodium polyacrylate and xanthan gum. The mixture is then brought to 75 ° C.

In the second container, the fat-soluble ingredients are mixed: propylheptyl caprylate, shea butter, cetearyl isononanoate, cetyl alcohol, hydrogenated polydecene, squalane, steareth-21, pentaerythrity1 distearate and steareth-2. This mixture is also brought to 75 ° C.

Once the two mixtures are perfectly homogeneous, the contents of the second container are transferred to the first container in a regular flow and with vigorous stirring. This stirring is maintained after the end of the transfer for a few minutes to produce the emulsion which will form the cream.

Then, in order to stabilize the emulsion, the mixture undergoes controlled progressive cooling.

When the mixture reaches a temperature of 60 ° C., dimethicone and o-cymen-5-ol are added thereto.

When it reaches a temperature of 40 ° C, chlorphenesin is added.

Finally, when its temperature drops to 30 ° C, the pH of the cream is adjusted by adding the necessary and sufficient quantity of citric acid.

Manufacturing is complete when the mixture reaches a temperature of 25 ° C.

The creams thus produced have been tested, with satisfactory results, in agreement with the results obtained with thermal water alone.

ίο

Claims (9)

1. Cosmetic and / or dermatological composition intended for the treatment of pruritic inflammatory dermatoses caused by neurogenic cutaneous inflammations comprising as active principle Uriage thermal water associated with the admissible ingredients in the cosmetic field, said composition having a soothing effect on said dermatoses and used to prevent and reduce excess stimulation and superficial accumulation of skin cells. 2. Cosmetic and / or dermatological composition according to claim 1, characterized in that it comprises between 5 and 20% by mass of Uriage thermal water. 3. Cosmetic and / or dermatological composition according to claim 1 or 2, characterized in that the Uriage thermal water comprises: - between 40 mg / L and 600 mg / L of calcium, and / or salts and / or derivatives thereof, - between 12.5 mg / L and 125 mg / L of magnesium, and / or salts and / or derivatives thereof, - between 0.455 mg / L and 45.5 mg / L of potassium, and / or of salts and / or derivatives thereof, - between 23.6 mg / L and 2360 mg / L of sodium, and / or of salts and / or derivatives thereof. 4. Cosmetic and / or dermatological composition according to any one of claims 1 to 3, characterized in that it is in the form of an eye contour fluid comprising: - 6% Uriage thermal water, - 5% dimethicone, 3% glycerin, - 3% of hydrogenated polyisobutene, - 2.5% butylene glycol, - 2.5% shea butter, - 1.5% of cetearyl ethylhexanoate, - 1.5% sodium polyacrylate, - 0.75% acrylates / Cl0-30 alkyl acrylate crosspolymer, - 0.40% chlorphenesin, - 0.15% o-cymen-5-ol, - 0.09% biosaccharide gum-1, - QSP 100 water. 5. Cosmetic and / or dermatological composition according to any one of claims 1 to 3, characterized in that it is in the form of an eye contour fluid comprising: - 9% Uriage thermal water, - 3% dimethicone, - 4% glycerin, - 2% of hydrogenated polyisobutene, - 2.5% butylene glycol, - 2.5% shea butter, - 1.5% of cetearyl ethylhexanoate, - 1.5% sodium polyacrylate, - 0.75% acrylates / Cl0-30 alkyl acrylate crosspolymer, - 0.40% chlorphenesin, - 0.15% o-cymen-5-ol, - 0.09% biosaccharide gum-1 and - water QSP 100 ,. 6. Cosmetic and / or dermatological composition according to any one of claims 1 to 3, characterized in that it is in the form of a light cream comprising: - 15% Uriage thermal water, - 7% propylheptyl caprylate, - 4% shea butter, - 4.5% of cetearyl isononanoate, - 1.5% cetyl alcohol, - 1.5% hydrogenated polydecene, - 1.5% squalane, - 2.5% butylene glycol, - 7% glycerin, - 2% steareth-21, - 1.2% pentaerythrityl distearate, - 1.5% sodium polyacrylate, - 0.75% steareth-2, - 0.40% chlorphenesin, - 0.20% citric acid, - 0.15% o-cymen-5-ol and 0.30% xanthan gum and - water QSP 100. 7. cosmetic and / or dermatological composition according to any one of claims 1 to 3, characterized in that it is in the form of a light cream comprising: - 12% Uriage thermal water, - 5% propylheptyl caprylate, - 2.5% shea butter, - 3% of cetearyl isononanoate, - 2.5% cetyl alcohol, - 1.5% hydrogenated polydecene, - 1.5% squalane, - 2.5% butylene glycol, - 7% glycerin, - 2% steareth-21, - 1.2% pentaerythrityl distearate, - 1.5% sodium polyacrylate, - 0.75% steareth-2, 0.40% chlorphenesin, - 0.20% citric acid, 0.15% o-cymen-5-ol, - 0.30% xanthan gum, and - QSP 100 water. 8. Cosmetic and / or dermatological composition according to any one of claims 1 to 3, characterized in that it is in the form of a rich cream comprising: - 18% Uriage thermal water, - 8% propylheptyl caprylate, - 5% shea butter, - 4% of cetearyl isononanoate, - 2% cetyl alcohol, - 2% hydrogenated polydecene, - 2% squalane, - 2.5% butylene glycol, - 1.5% dimethicone, - 5% glycerin, - 2% steareth-21, - 1.2% pentaerythrityl distearate, - 1.5% sodium polyacrylate, - 0.75% steareth-2, - 0.40% chlorphenesin, - 0.20% citric acid, - 0.15% o-cymen-5-ol, - 0.30% xanthan gum, and - QSP 100 water. 9. Cosmetic and / or dermatological composition any one of claims 1 to 3, characterized in that it is in the form of a cream comprising: - 20% Uriage thermal water, - 6% propylheptyl caprylate, - 6% shea butter, - 4% of cetearyl isononanoate, - 2% cetyl alcohol, - 2% hydrogenated polydecene, - 2% squalane, - 2.5% butylene glycol, - 1.5% dimethicone, - 5% glycerin, - 2% steareth-21, - 1.2% pentaerythrityl distearate, - 1.5% sodium polyacrylate, - 0.75% steareth-2, - 0.40% chlorphenesin, - 0.20% citric acid, - 0.15% o-cymen-5-ol, - 0.30% xanthan gum, and - QSP 100 water. according to in this rich